{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-034115","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.420863+00:00","generated_at":"2026-05-31T07:10:00.226772+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway","bullets":["FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.","Net loss for Q2 2024 was $3.0M ($1.01 per share) vs $2.6M ($1.94 per share) in Q2 2023; per-share reflects 1-for-20 reverse split.","Cash and cash equivalents $5.6M as of June 30, 2024; R&D expenses unchanged at $1.7M, G&A increased to $1.4M.","Preclinical NGC-Iri study shows greater SN-38 accumulation in tumor vs non-cancer tissues compared to irinotecan and Onivyde.","NGC-Cap Phase 1b data: 66.7% of patients had partial response or stable disease; progression-free survival 5-11 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-034115","json":"https://secwatch.observer/filing/0001493152-24-034115.json","markdown":"https://secwatch.observer/filing/0001493152-24-034115.md","text":"https://secwatch.observer/filing/0001493152-24-034115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224034115/0001493152-24-034115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224034115/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:10:00.226772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}